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The human Notch system consists of 5 ligands and 4 membrane receptors with promiscuous ligand binding, and Notch-initiated
signalling interacts with a wide range of other intracellular pathways. The receptor signalling seems important for regulation of
normal and malignant hematopoiesis, development of the cellular immune system, and regulation of immune responses. Several
Notch-targeting agents are now being developed, including natural receptor ligands, agonistic and antagonistic antibodies, and
inhibitors of intracellular Notch-initiated signalling. Some of these agents are in clinical trials, and several therapeutic strategies
seem possible in stem cell recipients: (i) agonists may be used for stem cell expansion and possibly to enhance posttransplant
lymphoid reconstitution; (ii) receptor-speciﬁc agonists or antagonists can be used for immunomodulation; (iii) Notch targeting
may have direct anticancer eﬀects. Although the eﬀects of therapeutic targeting are diﬃcult to predict due to promiscuous
ligand binding, targeting of this system may represent an opportunity to achieve combined eﬀects with earlier posttransplant
reconstitution, immunomodulation, or direct anticancer eﬀects.
1.Introduction
The most important members of the human Notch sys-
tem are the four Notch receptors and their ﬁve lig-
ands. Notch-mediated signalling is important in embryonic
hematopoiesis and development of the immune system,
regulation of the peripheral immune system, and devel-
opment of hematological malignancies, especially T cell
acute lymphoblastic leukemia (T-ALL) [1–3]. Thus, for
patients treated with allogeneic stem cell transplantation
for hematological malignancies, agonistic or antagonistic
targeting of Notch signalling may become useful to (i)
a c h i e v em o r ee ﬀective and safe antileukemic treatment and
thereby reduce the risk of posttransplant relapse through
direct targeting of the malignant cells, (ii) enhance T cell
reconstitution and thereby reduce posttransplant immune
defects, and (iii) develop new immunomodulatory strategies
that can reduce the risk of severe infections and severe
graft versus host disease (GVHD) without inhibition of graft
versus leukemia (GVL) eﬀects. Even a combination of these
eﬀects may become a possible treatment by careful selection
of molecular targets.
2.Notch Molecules, Notch Ligands,and
DownstreamSignalling
2.1. Notch and Notch Ligands. Humans possess the four
heterodimeric transmembrane Notch receptors Notch1-4
that can bind the ﬁve transmembrane ligands Delta-like 1,
3, and 4 (DLL1/3/4) and Jagged 1 and 2 (JAG1/2) (Figure 1).
The receptor chains are cleaved by a furin-like protease in
the Golgi apparatus during their way to the cell surface
where they form heterodimeric receptors. These receptors
consist of an extracellular subunit (NEC) with a distant part
with a variable number of glycosylated Epithelial growth2 Bone Marrow Research
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Figure 1: Notch receptors and their ligands. Signal-initiating cells
express Notch ligands of the Delta-like (DLL1, DDL3, DLL4)
or Jagged families (JAG1, JAG2). Common structural features
of all ligands are the Epithelial growth factor-like (EGF) repeats
and the distal amino-terminal domain called DSL (Delta, Serrate,
and Lag-2). DSL is involved in receptor binding. Additionally,
JAG1 and JAG2 contain a proximal cysteine-rich (CR) domain
between the EGF-like repeats and the plasma membrane. In
humans there are four heterodimeric Notch receptors (Notch1-4;
N1-N4). The extracellular Notch receptor domain contains EGF-
like repeats, a cysteine-rich LIN-12 repeats (LIN domain) that
prevents ligand-independent activation, and the proximal het-
erodimerization domain (HD). The cytoplasmic domain contains
an RBP-J-associated molecule (RAM) domain (closest to the cell
membrane) followed by ankyrin repeats (ANK) that bind to the
CSL (CBF1/RBP-Jκ/Suppressor of Hairless/LAG-1) transcription
factor, a transactivation domain (TAD; only Notch 1 and 2),
and a PEST (proline, glutamic acid, serine, threonine) sequence
that is important for stabilization of the protein (adapted from
[1]).
factor (EGF-) like repeats followed by LIN domains that
prevent ligand-independent activation. The transmembrane
and cytoplasmic (NTM) subunit consists of the cytoplasmic
RAM domain followed by ankyrine repeats that bind to the
eﬀector transcription factor CBF1, two nuclear localization
signals, a transactivation domain that is present only in
Notch1 and Notch2, and ﬁnally a PEST sequence involved
in stabilization of the protein.
The ﬁve ligands also diﬀer in their structure (Figure 1):
the amino-terminal DSL domain (Delta, Serrate, and Lag-
2) which is involved in receptor binding is common to
all ligands; this is followed by a variable number of EGF
repeats; JAG1/2 contains an additional C-terminal cysteine-
rich domain (CR). The Delta ligands seem to have two
activities: to trans-activate Notch in neighboring cells and
to cis-inhibit Notch in its own cells [5]. Glycosylation of
the extracellular Notch domain modulates ligand-initiated
Notch signalling; for example, with regard to one experi-
mental model DLL ligands were preferred over JAG ligands
when the receptors contained N-Acetylglucosamine on the
O-fucose residues in the EGF-like repeats [1, 6]. Notch
receptors seem to be promiscuous with regard to ligand
binding, although it should be emphasized that the ligand
speciﬁcityofthevariousreceptorshasnotbeencharacterized
in detail. Notch1, Notch2, and Notch3 can all be activated
by diﬀerent ligands like DLL1, JAG1/2 [7, 8]; however, as
mentioned, the ligand speciﬁcity of Notch1-4 has not been
characterized in detail.
2.2. Canonical Intracellular Signalling. The ﬁrst event in
canonical Notch signalling (Figure 2) is ligand-receptor
interaction with initiation of two successive proteolytic
cleavagesofthereceptors(atsitesS2andS3byADAMfamily
protease and the γ-secretase, resp.) and thereby the release of
the Notch IntraCellular Domain (NICD). NICD translocates
to the nucleus where it heterodimerizes with the DNA-
binding transcription factor CBF1 (also named CSL or Rbp-
j) and recruits other coactivators, including mastermind-like
proteins (MAML1-3) and the MED8-mediator transcription
activation complex; this leads to induction of transcrip-
tional expression of target genes. The Notch-associated gene
expression proﬁle will not depend on the receptor mediating
the signal only since binding of diﬀerent ligands to the same
receptor will in some cases have diﬀerent functional eﬀects
[1, 9].
2.3. Noncanonical Signalling. Noncanonical Notch signalling
is well documented [2, 10], but less characterized than
the canonical pathway. There are probably three types
of noncanonical Notch signalling: Type I involves Notch
ligation and translocation of activation signals independent
of CBF1 (NICD-dependent but CBF1-independent); Type
II involves activation of Notch target genes independent
of S3 cleavage (NICD- and CBF1-independent); Type III
involves CBF1-dependent gene activation without receptor
cleavage and NICD release [10]. Several signalling pathways
are involved, including Hedgehog, Jak/STAT, RTK, TGF,
Wnt,PI3/Akt,mTor/Akt,JNK,MEK/ERK,andNFκB[2,10].Bone Marrow Research 3
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Figure 2: Notch canonical signalling pathway. The ﬁgure shows an
overview of the canonical Notch signalling pathway (adapted from
[4]). The signalling is initiated by ligand binding to Notch receptor
(1). This binding initiates two subsequent proteolytic cleavages
of the Notch receptor by the ADAM family protease (2) and
the γ-secretase, respectively (3). The Notch IntraCellular Domain
(NICD) is thereby released to the cytoplasm (4) and translocates
to the nucleus where NICD heterodimerizes with the DNA-binding
transcription factor CBF1 (also named CSL or Rbp-j). Additional
coactivators are also recruited, including mastermind-like proteins
(MAML1-3) ultimately leading to induction of transcriptional
expression of downstream target genes, including those belonging
to the Hes and Hey families.
Noncanonical Notch signalling seems important for main-
tenance of lineage-restricted hematopoietic progenitors, and
several of the mediators involved in this signalling are in
additionimportantinleukemogenesisaswellasregulationof
cellular immune responses. The noncanonical pathway thus
represents a point of crosstalk between other intracellular
signalling pathways.
3.Notch andHematopoietic Progenitors
3.1. Notch in the Hematopoietic System. Notch1-mediated
signals are essential for generation of deﬁnitive Hematopoi-
etic stem cells (HSCs) during embryogenesis [11] though as
described in more detail below, canonical Notch signalling
seems to be dispensable for HSC maintenance in adults.
HSCs reside primarily in the bone marrow in a complex
microenvironment consisting of stromal cells, microvessels
and extracellular matrix. These cells have the dual ability
to self-renew as well as being able to give rise to all the
cells in the hematopoietic system. Mainly HSCs are in
a quiescent state; that is, the cells are in G0/G1 of the
cell cycle and do not proliferate. An important factor in
regulating the fate of HSCs in terms of HSC quiescence,
self-renewal and diﬀerentiation, is the surrounding stem cell
microenvironment, the so-called stem cell niche. HSCs have
been shown to be in close proximity to cells lining the
endosteum as well as near the specialised blood vessels in
bone marrow called sinusoids [12].
3.2. The Osteoblastic Stem Cell Niche. The osteoblastic niche
(also referred to as the endosteal niche) [13, 14] and the
vascular niche [12, 15] create a supportive environment for
stem cells. Notch signalling is thought to be a key signalling
pathway involved in maintenance and expansion of the HSC
pool. In addition, an important role of Notch signalling in
osteoblast and osteoclast homeostasis was recently described
[16, 17]. Hematopoietic progenitor cells express Notch
receptors and are exposed to Notch ligands in the bone
marrow such as expression of JAG1 and DLL1 by osteoblasts
[13, 18]. In a study by Calvi et al., parathyroid hormone
stimulation of osteoblasts in mice resulted in induced
osteoblastic proliferation with increased expression of JAG1
and a Notch1-mediated expansion of HSCs [13, 19]. These
observations identiﬁed Notch as an important component of
thestemcellnichethatsupportsosteoblasticHSCregulation.
However, further studies of osteoblastic regulation of HSCs
via the Notch pathway have yielded conﬂicting results. Using
serial transplantation studies, long-term reconstitution of
HSCs was shown to be impaired after inhibition of Notch
signalling [20]. In contrast, inactivation of neither JAG1
nor Notch1 impaired HSC maintenance in conditional
knockout mouse models [21]. In a study by Maillard et
al., Notch signalling was blocked by elimination of CBF1
and expression of dominant negative MAML mutants, and
canonical Notch signalling was shown to be dispensable for
the maintenance of long-term (LT) HSCs in vivo [22].
3.3. The Endothelial Stem Cell Niche. Endothelial cells pro-
mote HSCexpansion andself-renewal invitro andareshown
tohaveanimportantroleinengraftmentofHSCsandrecon-
stitutionofhematopoiesisinvivo[23].InhibitionofVEGFR-
2 signalling in sinusoidal endothelial cells impaired vascular
recovery and hematopoietic reconstitution following irradi-
ation in mice [23]. Thus, hematopoietic regeneration after
myeloablation depends on vascular recovery and endothelial
cell function, and Notch has been implicated in cell-cell4 Bone Marrow Research
interactionsbetweenHSCsandendothelialcellsthatregulate
HSC function. In vivo, sinusoidal endothelial cells express
Notch ligands JAG1 and JAG2 [24], and Notch-activated
HSCs have been visualised in close proximity to the bone
marrow vasculature [25] .Ar e c e n ts t u d yu s e da n g i o g e n i c
models to demonstrate that Notch signalling via endothelial
cells plays a role in regulation of HSCs in the vascular niche
[24]. Increased expression of Notch ligand on endothelial
cells after stimulation with soluble kit ligand stimulated the
expansion of repopulating CD34−Flt3−cKit+Lineage−Sca1+
LT-HSCs at the expense of reducing diﬀerentiation, and
serial transplantation assays demonstrated that these LT-
HSCs retained their self-renewal ability. Furthermore, in a
coculture model, endothelial cells failed to expand HSCs
derived from Notch1-/Notch2-deﬁcient mice.
3.4. Notch as a Part of an Interactive Cell Signalling Network.
Notch-initiatedsignallingispartofaninteractingnetworkof
intracellular signalling pathways. The noncanonical activa-
tionofNotch signallingrepresentsacrosstalkbetweenNotch
signalling and other intracellular signalling pathways (see
above). Interactions between Notch and the Wnt pathway
have been best characterized, but other interactions with
various pathways have also been described.
(i) Wnt-initiated signalling is mediated through the
downstream β-catenin [26]. The Wnt and Notch
pathways seem to act in synergy to maintain the stem
cell pool [26, 27]. The crosstalk between these two
pathways seems to occur at both the intracellular
level and between cells in the stem cell niche. Firstly,
members of the Wnt pathway regulate the expression
of established Notch target genes, and inhibition of
WntsignallingaﬀectstheexpressionofbothWntand
Notch target genes [20, 28]. Secondly, Wnt signalling
can aﬀect the expression of Notch1 as well as HoxB4
[29]. The HoxB4 transcription factor is important
for HSC self-renewal and expansion by inducing
the expression of genes preferentially expressed by
HSCs and downregulating genes associated with
myeloid diﬀerentiation [30, 31]. Finally, an example
of extrinsic crosstalk between these two pathways
in the stem cell niche is the induced expression of
Notch ligands by activated β-catenin in stromal cells
which thereby induce-Notch-mediated intracellular
signalling in adjacent HSCs [32].
(ii) Notch signalling becomes a part of a more extensive
network through its crosstalk with the Wnt pathway
that interacts with several other intracellular path-
ways [27], including (i) Hedgehog signalling [33],
(ii) Prostaglandin E2 signalling; animal experiments
suggest that this crosstalk is dependent on a pro-
tein kinase A-dependent mechanism that connects
the pathways via β-catenin [34], (iii) Transforming
growth factor-β (TGF-β) and Bone morphogenic
protein (BMP) signaling which targets the common
intracellular mediator Smad4 that directly interacts
with members of the Hox transcription factor family
[26, 35], and (iv) Angiopoietin-1/Tie2 signalling
which is also important in HSCs [36]; this signalling
targetsCdh2(N-cadherin)[37]thatseemstoactivate
β-catenin signalling through protein kinase B (Akt-)
dependent mechanisms [38].
(iii) Hey2 is a transcription factor that seems to act
downstream of Notch in primitive hematopoietic
cells, and studies in zebraﬁsh suggest that its expres-
sion is maintained by Hedgehog as well as Vascular
endothelial growth factor signalling [39].
(iv) Several members of the NF-κB family (including
p65, p50, RelB, and c-Rel) are under transcriptional
control by Notch-initiated signaling, and decreased
levels were found in Notch-1 antisense transgenic
(Notch-AS-Tg) mice [40]. NF-κBi sa ni m p o r t a n t
regulator of the expression of several chemokines,
and Notch-initiated signalling may thereby aﬀect
chemotaxis and cell traﬃcking [41, 42].
(v) The Ets transcription factor Er71 seems to be a
commondownstreamtargetboth fortheWnt,Notch
and BMP signalling pathways [43].
TheseobservationsclearlyillustratethatNotchsignalling
ispartofanextensivenetworkofinteractingpathways.These
pathways are important for normal HSCs, and several of
them are also important in the development of myeloid
malignancies.BesidesNotchsignallingpathways(seebelow),
the extensive network of interacting pathways includes the
Wnt pathway [44, 45], Ang-1/Tie2 [46], HoxB4 [44, 47],
Hedgehog signalling [44], BMP [35], NF-κB[ 48], and TGF-
β/Smad4 [35, 49] signaling pathways. Thus, Notch signalling
is a part of an extensive network involving several interacting
pathways both in normal and leukemic hematopoietic cells.
4.Notch Signallinginthe Immune System
4.1. The Role of Notch in T Cell Development. Notch
signalling is directly involved in the regulation of thymic
T cell development with Notch1 acting as a key receptor
responsible both for the lineage commitment and inhibition
of other diﬀerentiation directions [1]. The DLL4 ligand
is expressed by thymic epithelial cells and is essential
for T lineage commitment [50]( Table 1). The αβ Tc e l l
development depends on Notch signalling, and transition
through the β-selection checkpoint is then dependent on
both Notch signalling [1]a sw e l la sC X C L 1 2l i g a t i o no f
CXCR4 with initiation of PI3K signalling [51]. Notch1
expressionisdownregulatedafterβ-selection[1].Incontrast,
the γδ T cell development seems less dependent on Notch
signalling.
4.2. Eﬀects of Notch on Peripheral T Cell Subsets. Naive T
cells exit the thymus and migrate to the periphery where
they mediate immune responses after antigenic recognition
together with adequate costimulation. Activated naive CD4+
T helper cells (Th0 cells) can diﬀerentiate towards Th1,
Th2, Th9, Th17, and Th22 helper cells, or they may
alternatively develop into induced regulatory T (iTreg) cells
that act together with thymus-derived natural T regulatoryBone Marrow Research 5
Table 1: Notch ligand-receptor interaction: a summary of possible interactions involved in normal hematopoiesis, T cell development, and
regulation of the peripheral T cell system.
SIGNAL-INITIATING CELL SIGNAL-RECEIVING CELL
Cell type Ligand Cell type Receptor References
Bone marrow stromal cells Bone marrow stem cells
Osteoblasts (endosteal niche) JAG1 Sca-1+,c - k i t +, Lin− Notch1 [13]
JAG1, JAG2 Sca-1+,c - k i t +, CD117+ Notch1, Notch2 [52]
Endothelial cells (vascular niche) JAG1, JAG2, DLL4, DLL1 Sca-1+,c - k i t +, Lin− Notch1, Notch2 [24]
Thymic epithelial cells (TECs) T cell progenitors
TECs DLL4 Thymocytes Notch1 [1, 50]
Antigen-presenting cells Peripheral T cells
APC DLL1 Tc Notch1, Notch2 [1]
DC DLL1, DLL4 Th1 Notch3 [1, 4, 53]
DC JAG1, JAG2 Th2 Notch1, Notch2 [1, 4, 53]
APC DLL1, DLL4 Th17 Notch [1, 54]
pDC DLL4 Th1 IL-10+ Notch [55]
Abbreviations: Delta-like (DLL); Jagged (JAG); Thymicepithelialcells (TECs); Antigenpresenting cells (APC); Dendriticcells (DC);plasmacytoidDC(pDC);
Cytotoxic T cells (Tc); Helper T cells (Th); Interleukin-10 (IL-10).
(nTreg) cells to inhibit immune responses. Activation of
naive CD8+ T cells leads to the diﬀerentiation towards
cytotoxic T lymphocytes (Tc, or also called CTLs). A detailed
list of possible interactions between ligand-presenting and
receptor-expressing cells involved in normal hematopoiesis,
T cell development, and T cell activation is given in Table 1.
4.2.1. Tc Cells. The transcriptional regulator eomesodermin
(Eomes)regulatestheexpressionofperforinandgranzymeB
in CD8+ cytotoxic T cells [56]. Notch1 seems to directly reg-
u l a t ee x p r e s s i o no fE o m e sa sw e l la sp e r f o r i na n dG r a n z y m e
B by binding to their promoters, and γ-secretase inhibitors
(GSIs) thereby attenuate in vitro T cell cytotoxicity. In
addition,Notch2-ICDseemstocooperatewithCREB1inthe
regulation of granzyme B expression [57].
4.2.2. Th1 and Th2 Cells. Th1 cells produce IFNγ while
Th2 cells produce IL-4, IL-5, and IL-13 as their signature
cytokines. Jagged ligands expressed by APCs are important
for Th2 diﬀerentiation whereas DLL ligands (DLL1 and/or
DLL4) seem to promote Th1 and inhibit Th2 diﬀerentiation,
but the additional molecular events in this diﬀerentiation
have not been characterized [1] .T h u s ,i ti sn o tk n o w n
which Notch receptors mediate the DLL-induced Th1 cell
diﬀerentiation signal. Although canonical Notch signalling
does not seem to be essential [1], Notch3 signalling is
possibly also involved in Th1 diﬀerentiation [58]. On the
o t h e rh a n d ,T h 2c e l ld i ﬀerentiation seems to involve CBF1
and IL-4, as well as the Th2-speciﬁc transcription factor
Gata3 that is a Notch target gene [58].
4.2.3. Th17 Cells. These cells represent a proinﬂammatory
subset distinct from Th1 cells; their signature cytokines are
IL-17A, IL-21, and IL-22, and they express the Th17-speciﬁc
transcription factor RORγ. DLL ligands might play a role in
the generation of Th17 cells [1], and recent in vitro studies
[54] suggest that DLL4 inhibits Th2 cytokine production,
c o n t r i b u t e st oT h 1 7d i ﬀerentiation, and upregulates RORc
expression. Both the RORc and IL-17 gene promoters then
seem to be direct targets for Notch-initiated signalling.
4.2.4. Treg Cells. Both natural (nTreg) and peripherally
induced Treg (iTreg) cells are important for downregulation
of immune responses. FoxP3 is a Treg-speciﬁc transcription
factor, and the cells typically release IL-10. Notch ligands
(usually the Jagged family) increase Treg cell diﬀerentiation
in vitro [1, 4, 59, 60], but this diﬀerentiation is not Notch-
dependent because Notch loss-of-function mutant mice do
not lack Treg cells [1]. Notch1 signalling seems to contribute
to the FoxP3 expression [61], and Notch3 receptors are
increased on murine CD4+CD25+ Treg cells [62]; exposure
to JAG2-overexpressing hematopoietic progenitors seems to
increase the expression of Notch3 and FoxP3 in Treg cells
[63].
4.3. Notch and Autoimmunity. There are few reports of
Notch in human autoimmune diseases. Recently Jiao et al.
[64] reported increased expression of Notch2/3/4 in Th
cells from patients with active rheumatoid arthritis, and
the increased expression of Notch3 was mainly detected in
activated T cells. These patients also show increased nuclear
t r a n s l o c a t i o no fN I C Di nT hc e l l sa sw e l la si n c r e a s e d
expression of the Notch target gene HES-1 [64]. Another
recent study [65] reported increased expression of Notch1/3
and decreased Notch2 together with downregulated DLL1
among peripheral blood mononuclear cells from patients
with autoimmune thrombocytopenia. Finally, Sodsai et al.
[66] suggest that defective Notch1 upregulation during T
cell activation is important for increased disease activity
in patients with systemic lupus erythematosus. However, it
should be emphasized that a major part of these studies only
included a description of Notch/Notch ligand expression
in immunocompetent cells; it is therefore diﬃcult to judge6 Bone Marrow Research
whether this altered expression is directly involved in dis-
ease development/progression or only represents secondary
(innocent bystander or secondary) eﬀects that may not be
clinically important.
The importance of Notch signalling in autoimmune
diseases has been investigated more in detail in murine
models of autoimmune disorders, and these results are
summarized in Table 2. The contribution of Notch signalling
has especially been investigated in experimental autoim-
mune encephalomyelitis (EAE), an experimental model of
multiple sclerosis. Th1 and Th17 cells are important for
the development of this disease, and inhibitions of Notch3,
γ-secretase, or DLL1 inhibit proinﬂammatory Th1/Th17
responsesandimprovediseasesymptoms.Incontrast,DLL2-
initiated signalling increases symptoms whereas JAG1 results
in improvement. Furthermore, Notch1-induced signalling
also seems important for the development of autoimmunity
in other organs, but these eﬀects seem to diﬀer depending on
the experimental model. Finally, Notch-induced signalling
with induction of Treg cells can inhibit the development of
autoimmune diabetes in various disease models. It should be
emphasizedthatseveraloftheseconclusionsarebasedonthe
observed eﬀects when using speciﬁc Notch inhibition in the
experimental models (like speciﬁc neutralizing antibodies)
as described in detail in Table 2; these eﬀects of speciﬁc
inhibitors demonstrate that Notch-initiated signalling is
directly involved in the regulation of experimental murine
autoimmunity.
Many clinical and laboratory features of GVHD, espe-
cially in its chronic form, resemble those of autoimmune
diseases, and the pathophysiological mechanisms also seem
to show similarities [72, 73]. Autoimmune phenomena can
be seen after both auto- and allotransplantation, and the
mostcommonmanifestations seemtobe thyroiddisease and
autoimmune cytopenias. Certain manifestations of GVHD
have been postulated to represent a speciﬁc loss of tolerance
to self structures. Taken together, these observations suggest
that the role of Notch signalling in autoimmune diseases is
relevant also for development of GVHD.
5. Immune Reconstitution after Stem
CellTransplantation
Immunological reconstitution after stem cell transplantation
has been extensively reviewed previously [74–78], and the
most important observations both in allogeneic and autol-
ogous transplantation are (i) early lymphoid reconstitution
is associated with a decreased risk of relapse, suggesting
that antileukemic immune reactivity is mediated early after
transplantation [79–82] and (ii) a long-lasting quantitative
CD4 T cell defect can persist for several months post
transplant [75, 76, 78].
The quantitative CD4+ T cell defect after allotransplan-
tation may last for several months, but early normalization
seems more common after reduced intensity conditioning
[78]. Infusion of a high number of CD4+ T cells and Natural
Killer (NK) T cells seems to be associated with a better
prognosis [83], an observation supporting the hypothesis
that early antileukemic immune reactivity is important.
Recovery of dendritic cells occurs more slowly [84], and an
abnormal ratio between various dendritic cell subsets may
persist for months after transplantation [84]. Low dendritic
cell counts one month post transplant also seem to be
an independent adverse prognostic factor for the overall
survival [85].
In autotransplanted patients the immunological recon-
stitution diﬀers between patients receiving peripheral blood
and bone marrow autografts [86]. Mobilized stem cells are
now most commonly used, and during the ﬁrst posttrans-
plant months the patients generally show early recovery
of CD8+ T cells, CD14+ monocytes, and CD56+ NK cells
[86–88]. Circulating dendritic cells are usually normalized
relatively early, although diﬀerences in dendritic cell subset
composition may persist for several months also in these
patients [88]. The T cell defect is detected after 6 months for
most of thesepatients andmay lastformore thana year[87],
and it is mainly due to reduced naive CD3+CD4+CD45RA+
T cells, but reduced CD8+ naive T cells can also be seen
[87, 88].
6.Notch inHematologicalMalignancies
6.1.T-LineageAcuteLymphoblasticLeukemia. ALLischarac-
terized by accumulation of immature lymphoblast of either
B or T cell lineage origin in bone marrow and eventually
other lymphoid organs. T-ALL accounts for approximately
one third of all cases [89]. Notch involvement in T-ALL was
ﬁrst described in patients with the rare t(7;9) (q43;q34.3)
translocation that leads to the expression of a cytoplasmic
form of the Notch1 receptor with constitutive activity [90].
However, the most common Notch abnormality in T-ALL
is mutations in the Notch1 alleles that result in constitutive
activation of the pathway; this is seen in more than half
of the patients [91]. These Notch1 mutations are located
at speciﬁc hotspots and aﬀect critical negative regulatory
elements of the protein. The molecular mechanisms by
which aberrant Notch1 signalling contributes to T-cell trans-
formation are not yet fully understood. Oncogenic Notch1
probably cooperates with oncogenic transcription factors
such as c-Myc [92], E2A-PBX [93], and Ikaros [94], but
the aberrant Notch1 signalling is not suﬃcient for leukemic
transformation [95]. Observations in animal models suggest
that even nonmutational Notch1 activation contributes to
leukemogenesis [96], probably through activation of c-Myc
that is a direct downstream target of Notch1 [92]. Finally, the
prognosticimpactofNotch1mutationswasdemonstratedin
recent clinical studies where the mutations were associated
with good prognosis both in children [97] and adults [98].
6.2. Acute Myeloid Leukemia. The prevalence of Notch
mutation in AML is probably less than 5% [99, 100], and
Notch ligation in AML cells has diverse or only minor
eﬀects [101]. AML cells seem to express JAG1, Notch1 and
Notch2[102–104].Inhematopoiesis,Notch1,drivesmyeloid
diﬀerentiation through the expression of transcriptional
factor PU.1. Results obtained from Chen et al. in [104]Bone Marrow Research 7
Table 2: Therapeutic targeting of Notch in murine autoimmunity in vivo.
Disease and intervention Therapeutic eﬀect References
Experimental autoimmune encephalomyelitis (EAE; model of multiple sclerosis)
γ-secretase inhibitor Inhibition of disease-associated Th1 responses and
improvement of symptoms [4, 58, 67]
Notch1 neutralizing antibodies No eﬀect on Th1 and Th17 responses [4, 58]
Notch3 neutralizing antibodies Decreased Th1 and Th17 responses, inhibition of the ability of
myelin-primed T cells to transfer the disease [4, 58]
DLL1 neutralizing antibodies Reduced Th1 responses and EAE symptoms [4, 68]
Activating DLL1-Fc fusion protein Increased Th1 responses and EAE symptoms [4, 68]
Neutralizing JAG1 antibodies EAE disease progression [4, 68]
Activating JAG1-Fc fusion protein Improvement of EAE symptoms [4, 68]
Experimental hepatitis
γ-secretase inhibitor
Reduced Notch1 signalling and FoxP3 expression, spontaneous
hepatic lymphocyte inﬁltration consistent with autoimmune
hepatitis (C57BL/6 mice)
[61]
Murine diabetes
Lck-Notch3-IC transgenic mice
Up regulation of the generation and function of CD4+CD25+
Treg. The mice failed to develop streptozotocin-induced
autoimmune diabetes. Adoptive transfer of the lck-Notch3-IC
transgenic CD4+ cells to wild-type recipients prevented the
progression of the disease.
[62]
Exposure to JAG2-expressing
hematopoietic progenitor cells
Activation of Notch3 signalling with increased Treg
proliferation and prevention of diabetes in NOD mice. [63]
Multiorgan autoimmune disease
Loss of functional mutation in the Itch
ubiquitin ligase
This ligase is involved in Notch1 degradation; homozygous
mice develop an autoimmune-like disease mainly aﬀecting
lungs, skin, and lymphoid organs.
[2, 69–71]
Abbreviations: Experimental autoimmune encephalomyelitis (EAE), Delta-like (DLL), Jagged (JAG), Helper T cells (Th).
show that the Notch1 gene and protein expression were
decreased in human AML samples in comparison with
normal hematopoietic stem cells. This decrease of Notch1
expression was associated with a concordant downregulation
in PU.1, suggestive of impeded PU.1-mediated myeloid sig-
nalling and thus contributing to AML leukemogenesis [104].
However, gene expression proﬁling of primary human AML
cells has identiﬁed a subgroup of patients with recurring
mutations in Notch [105, 106]; the expression proﬁle of
these patients seems to be mainly determined by silencing
of the CEBPA gene through promoter hypermethylation
[106]. The CEBPA gene encodes for the transcription factor
CCAAT/enhancer-binding protein alpha (C/EBPalfa); this
gene is mutated in approximately 10% of AML cases [107].
AML cells with silenced CEBPA gene and Notch mutations
cluster together [106].
6.3. Chronic Lymphocytic Leukemia. Chronic lymphocytic
leukemia (CLL) is characterized by detection of malignant
CD5+CD19+ B cells in blood, bone marrow, and eventually
other lymphoid organs. Several recent studies suggest that
the Notch system is important also in B-CLL. Firstly,
B-CLL cells express high levels of Notch2 that regulate
the expression of antiapoptotic CD23a [108]. Secondly,
Notch1/2 and the ligands JAG1/2 are also constitutively
expressed in B-CLL [109] and are then associated with
resistance to apoptosis [109]. Upregulation of Notch1 is
observed during treatment with the MDM2/p53 inhibitor
Nutlin-3 and possibly represents a feedback mechanism
involved in restrain of the Nutlin-3 eﬀects [110].
7. Possible Strategies for
NotchTargetinginPatientsTreatedwith
Stem CellTransplantation
7.1. Therapeutic Tools for Inhibition of Canonical Notch
Signalling. An overview of possible therapeutic tools is
given in Table 3. The tools include ligands, agonistic and
antagonistic antibodies, stimulatory fusion proteins, and
inhibitors of intracellular signalling. Inhibition of the γ-
secretase activity with general downregulation of Notch
signalling has been used in experimental in vitro studies
[111]. Unless NICD is translocated to the nucleus, the NICD
form of Notch is ubiquitinated and thereafter degraded
by the proteasomes; and proteasomal inhibitors may thus
enhanceNotchsignalling.Variousproteasomalinhibitorsare
now used in the treatment of hematologic malignancies, and
they are also tried as immunosuppressive agents [112–115],
but it is not known whether inhibition of Notch signalling
contributes to their clinical eﬀects.
The results summarized in Table 3 suggest that if a
detailed characterization of the immune system is available,8 Bone Marrow Research
Table 3: Potential molecular tools for targeting of Notch signalling.
Molecular tool Observations in clinical or experimental studies References
Natural receptor ligands
JAG2-expressing hematopoietic
progenitor cells
Activation of Notch3 signalling with increased Treg
proliferation and prevention of diabetes in NOD mice. [63]
Fusion proteins of natural ligands and
Fc-Ig
DLL1-IgG-Fc has been used for expansion of human umbilical
cord stem cell expansion; cells caused no unexpected toxicity
and contributed to long-term engraftment. Could be used for
transplantation.
[116]
JAG1- and DLL2-Fc fusion proteins Both types of fusion proteins have shown immunomodulatory
eﬀects in experimental murine disease models. [4, 68]
Receptor- or ligand-directed antibodies
Agonistic antibodies Agonistic antibodies have been identiﬁed for their reactivity
against Notch2 or Notch3. [117, 118]
Antagonistic antibodies directed against
Notch
Several antagonistic Notch1-, Notch2- or Notch3-directed
antibodies have been tested in vitro and in vivo.
[4, 58, 117,
119, 120]
Antagonistic antibodies directed against
Notch ligands
Both DLL- and JAG1- speciﬁc antibodies show
immunomodulatory eﬀects in murine disease models. [4, 68]
DLL1 neutralizing antibodies Reduced Th1 responses and improvement of EAE symptoms. [4, 68]
DLL4 neutralizing antibodies
In CSC-driven colon and breast xenograft models, anti-human
DLL4-blocking antibodies inhibited tumour growth and
reduced tumour-initiating cell frequencies.
[121]
Antibodies that inhibit the
transcription-regulating complex
Development of such antibodies could inhibit parts of the
Notch-initiating eﬀects and possibly limit the toxicity. [122]
Activating JAG1-Fc fusion protein Improvement of EAE symptoms. [4, 68]
Activating DLL2-Fc fusion protein Increased Th1 responses and progression of EAE symptoms. [4, 68]
Inhibition of intracellular signalling
γ-secretase inhibitor Reduced Notch1 signalling and FoxP3 expression in Treg cells in
murine disease models. [58, 61, 67]
Proteasome inhibitors Inhibition of noncanonical Notch signalling. [2, 10, 123,
124]
Inhibition of the PI3K-Akt-mTOR
pathway Inhibition of noncanonical Notch signalling. [2, 10, 48]
Peptide that inhibits assembly of the
transcription-regulating complex
The small hydrocarbond-staple peptide SAHM1 inhibits Notch
signalling in vitro. [122]
Abbreviations: Experimental autoimmune encephalomyelitis (EAE), Delta-like (DLL), Jagged (JAG), Helper T cells (Th), Cancer stem cell (CSC).
it would be possible to design therapeutic strategies based
on stimulation or inhibition of selected Notch-mediated
eﬀects. Especially in allograft recipients, Notch inhibition
may oﬀer the opportunity to combine immunosuppressive
GVHD prophylaxis with direct antileukemic eﬀects.
7.2. Notch-Driven Stem Cell Expansion Eﬀects on Posttrans-
plant Myeloid Reconstitution. The delayed hematopoietic
stem cell engraftment commonly seen after cord blood
transplantation is probably due to an inadequate numbers
of progenitor cells in the graft [116]. In a recent phase I
clinical trial, CD34+ cord blood cells were cultured ex vivo
with the extracellular DLL1 domain fused to the Fc domain
of human IgG. After 16 days and following myeloablative
conditioning, the expanded cells were transplanted together
withanunmanipulatedallograft.Nounexpectedtoxicitywas
observed, and the patients showed early myeloid reconstitu-
tion with a shortened time until peripheral blood neutrophil
counts ≥0.5 × 109/L (16 days compared with 26 days
for the controls). In four of these patients, the neutrophil
reconstitutionwasattainedatatimewhenatleast80%ofthe
cells were derived from the manipulated grafts, and for two
patients,long-termpersistenceofthesecellswasdocumented
after 180 and 240 days. For other patients, persisting cells
were derived from the unmanipulated graft. Thus, targeting
of Notch can be used for ex vivo stem cell expansion of
allogeneic stem cells. Whether a similar methodological
approach can be used for ex vivo expansion of autologous
stem cells in poor mobilizers has not been investigated, but
the use of a CXCR4 antagonist would at present be the
ﬁrst alternative for such patients [125]. Another possible
therapeutic strategy may be in vivo expansion of stem
and progenitor cells by administration of the Delta1-IgG
preparation.
7.3. Notch Targeting and Posttransplant Lymphoid Reconsti-
tution. Early lymphoid reconstitution after stem cell trans-
plantation is associated with decreased relapse risk in severalBone Marrow Research 9
hematological malignancies [126]. The study by Delaney
et al. [116] demonstrated that ex vivo stem cell expansion
reduced the time until neutrophil reconstitution, but the
manipulated grafts did not contain T cells, and long-term
T cell engraftment was always derived from the unmanip-
ulated grafts (see above). Notch-induced signalling is also
important for T lymphopoiesis, but it is not known whether
alternative ex vivo or in vivo strategies for Notch targeting
can be used to increase lymphopoiesis and thereby shorten
the time until lymphoid reconstitution and thereby shorten
the posttransplant CD4 defect. Such a strategy may become
usefulinautotransplantedpatientstoincreaseposttransplant
antileukemic T cell reactivity, whereas it would be more
diﬃcult to use in allotransplanted patients with the risk of
severe and potentially lethal GVHD.
7.4. Notch Targeting of Malignant Hematopoietic Cells—
The Initial Clinical Experience. Allogeneic and autologous
stem cell transplantation is mainly used in the treatment
of hematologic malignancies, and Notch signalling seems
important in these diseases, especially T-ALL (see above).
Inhibitors of the γ-secretase activity have been developed,
but the initial clinical Phase I studies in T-ALL patients
showed a low eﬃciency and severe gastrointestinal toxicity
[127]. Several other Notch-targeting drugs are now being
developed for use in clinical phase 1-2 trials, and one of
themhasalsobeeninvestigatedinaphase3trial[128].These
agents are mainly γ-secretase inhibitors that are tried in the
treatment of various cancers. Whether these inhibitors will
have an acceptable toxicity and higher eﬃciency has to be
addressed in future studies.
7.5. Targeting Noncanonical Notch Signalling—Possible Mech-
anisms for the Antileukemic Eﬀects of Several Targeted Ther-
apies. Several drugs may aﬀect the expression of Notch-
targeted genes through inhibition of the noncanonical
pathways such as HSP90, HDAC, PI3K/Akt/mTOR, and
proteasomal inhibitors [2, 10]. Some of these drugs may
have combined eﬀects; for example, proteasomal inhibitors
may alter noncanonical signalling through NFκB inhibition
together with decreased degradation of the NICD form
involved in canonical signalling. Furthermore, speciﬁc PI3K
inhibitors are now evaluated in clinical studies [129]. The
PI3K-Akt pathway is upstream to mTOR, and the mTOR
inhibitor rapamycin is used for immunosuppression after
allotransplantation and is also being investigated as an
anticancer agent in hematologic malignancies. Thus, Notch
inhibition may contribute to the eﬃciency of several new
anticancer and/or immunosuppressive-targeted therapeu-
tics.
7.6. Notch Targeting in Stem Cell Recipients: Immunosuppres-
sion versus Immunostimulation. As can be seen from Table 2,
Notch targeting can be used both for immunostimulation
and immunosuppression in experimental autoimmunity,
and these observations may be relevant also for human
GVHD [72, 73]. Thus, Notch signalling seems important
bothforTlymphopoiesisandforregulationoftheperipheral
Tc e l ls y s t e m .N o t c ha g o n i s t sm a yt h u sb e c o m eu s e f u lt o
enhance T cell reconstitution after both allogeneic and
autologous stem cell transplantation. Early lymphoid recon-
stitution is then associated with decreased risk of cancer
relapse, and earlier T cell reconstitution would possibly
further reduce the relapse risk. T cell defects are in addition
associated with an increase of severe opportunistic infections
especially in allotransplant recipients [130, 131], and early
reconstitution may also reduce this risk. On the other hand,
enhancement of T cell reconstitution after allotransplanta-
tion has to be balanced against a possible risk of inducing
severe and potentially lethal GVHD.
A second possibility could be to use Notch-targeting
therapy to modulate the function of peripheral T cells.
Immunostimulatory agonists could then be used to enhance
antileukemic immune reactivity after autologous stem cell
transplantation. Clinical studies have demonstrated that
a n t i l e u k e m i cTc e l l sc a nb ed e t e c t e di na u t o t r a n s p l a n t e d
leukemia patients and that this reactivity can possibly be
enhanced by vaccination therapy [126]. Immunostimula-
tory Notch targeting may then increase this antileukemic
reactivity and possibly increase the eﬃciency of anticancer
vaccines.
A third strategy is to consider immunomodulatory
strategies to reduce the risk of severe GVHD after allotrans-
plantation. Yvon et al. [132] overexpressed the JAG1 ligand
in alloantigen-presenting B cells and observed induction of
Treg cells from CD45-RA+ T cells;these allospeciﬁcTreg cells
caused a speciﬁc inhibition of proliferative and cytotoxic T
cell responses against the priming alloantigens. Thus, Notch
agonists may be used to induce speciﬁc tolerance against
alloantigens, and both ex vivo generation of immunoregu-
latory cells and in vivo administration of agonists should be
considered. An alternative would be to use Notch inhibition
for suppression of eﬀector T cells (see Table 2). However,
the use of Notch inhibition in targeting the peripheral T
cell system seems less attractive because this approach may
interfere with lymphoid reconstitution and aggravates the
posttransplant T cell defects (see above).
7.7. Mesenchymal Stromal Cells. Multipotent mesenchymal
stromal cells (MSCs), also called mesenchymal stem cells,
are able to diﬀerentiate into a variety of cell types includ-
ing osteoblasts, chondrocytes, and adipocytes [133]. These
cells are important components of the bone marrow HSC
niche and can support HSC maintenance and engraftment
[134]. Intriguingly, MSCs have also been shown to have
immunomodulatory properties which are of value in a
clinical setting with regard to treatment of GVHD after
hematopoietic stem cell transplantation (HSCT). More-
over, cotransplantation of HSCs and MSCs can facilitate
hematopoietic engraftment and was shown to accelerate
lymphocyte recovery in clinical HSCTs [135]. The exact
mechanisms of how MSCs contribute to hematopoietic
reconstitution remain unclear though both immunomod-
ulatory eﬀects as well as eﬀects on HSC self-renewal
capacity are assumed and Notch signalling has been impli-
cated in these eﬀects. Studies of Notch function have10 Bone Marrow Research
revealed that Notch signalling aﬀects various diﬀerentiation
capabilities of MSC, including diﬀerentiation in direction
of osteoblasts [17, 136, 137]. Notch signalling in bone
marrow is suggested to maintain a pool of mesenchymal
progenitors by suppressing osteoblast diﬀerentiation [16]. In
addition, Notch signalling has been identiﬁed as a possible
pathway involved in osteogenic diﬀerentiation of MSCs
induced by soluble mediators derived from endothelial cells
[138].
The infusion of MSCs has been tried in the treat-
ment of GVHD. There seems to be a consensus that
these cells are immunomodulatory, but the initial clini-
cal studies have shown conﬂicting results with regard to
the eﬃciency of MSC in the treatment of GVHD [139–
141]. Human bone marrow-derived MSCs were found to
express high levels of functionally active toll-like receptors
(TLR) 3 and 4, and these cells had an immunosuppressive
eﬀect on T-cell proliferation after ligation of either TLR3
or TLR4. Suppression of T-cell activation was inhibited
by neutralization of JAG1 and inhibition of γ-secretase
a c t i v i t y ,t h u si m p l y i n gar o l eo fi m p a i r e dN o t c hr e c e p t o r
signalling in T cells [142]. Additional mechanisms possibly
involved in MSC-induced immunomodulation could be
interactions with the NK cell system, inhibition of dendritic
cell diﬀerentiation, or modulation of the humoral system
[139].
Toconclude,eventhoughadditionalstudiesaredeﬁnitely
needed, these studies suggest that Notch signalling may be
important both for the development of supportive cells in
stem cell niches and for the immunomodulatory/GVHD-
suppressing eﬀect of the MSC.
7.8. Concluding Remarks. The Notch ligand/receptor system
is important for (i) development and regulation of the T
c e l ls y s t e ma n d( i i )r e g u l a t i o no fn o r m a la sw e l la sl e u k e m i c
hematopoiesis. The ﬁnal biological eﬀects of Notch targeting
in stem cell recipients are diﬃcult to predict, and depend
both on the involved ligand(s) and receptors, and signalling
through the canonical intracellular pathway is modulated by
noncanonical signalling. The interactions between Notch-
initiated signalling and several other intracellular signalling
pathways further make it diﬃcult to predict the ﬁnal
eﬀect of Notch-targeted therapy. Pharmacological tools
for targeting of Notch-mediated signalling are now being
developed. However, because the eﬀects of Notch-targeted
therapy are diﬃcult to predict a more detailed study of
the post-transplant hematopoiesis as well as the T cell
system is necessary before clinical studies of these agents
in transplant recipients can be designed. However, such
studies should be encouraged because Notch targeting may
represent a unique possibility to combine enhancement of
reconstitution, immunomodulation, and direct anticancer
treatment.
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